drugset / Trial / NCT01370694
Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001)
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the safety, pharmacokinetics, and anti-tumor activity of MK-8808 in combination with cyclophosphamide, vincristine, and prednisolone (CVP), and as a single agent, for participants with B-lymphocyte antigen cluster of differentiation 20 (CD20)-positive follicular lymphoma who have had no prior chemotherapy. The primary study hypothesis is that MK-8808 will be safe and well tolerated in combination with CVP and as a single agent.
Timeline
- Start
- 2011-08-19
- Primary completion
- 2014-12-01
- Completion
- 2014-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MK-8808 | Unknown | 375 mg/m2 | — |
| Background | Cyclophosphamide | Other / unclassified | 750 mg/m2 | Intravenous |
| Background | Prednisolone | Other / unclassified | 40 mg/m2 | Oral |
| Background | Vincristine | Small molecule | 1.4 mg/m2 | Intravenous |